Biotechnology company Moderna (NASDAQ: MRNA) announced better-than-expected revenue in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2% above analysts’ consensus estimates.

Is now the time to buy MRNA? Find out in our full research report (it’s free for active Edge members).

Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S. launch of MNEXT Spike, improved operational efficiency, and disciplined expense controls as key contributors. CEO Stéphane Bancel highlighted that operating expenses fell by 31% year over year, while President Stephen Hoge noted, “MNEXT Spike quickly became our leading product in the U.S.” The leadership acknowledged ongoing challenges, particularly the uncertainty caused by the FDA’s refusal to file letter on the mRNA-1010 flu vaccine, which management described as a source of “real challenges for businesses, patients, and the broader innovation ecosystem.”

Looking forward, Moderna’s growth strategy hinges on expanding international commercial partnerships, further uptake of its new COVID vaccine MNEXT Spike, and regulatory progress across its pipeline. Management anticipates up to 10% revenue growth in 2026, driven by increased contributions from the U.K., Canada, and Australia. CFO James Mock stated that full-year guidance assumes no revenue from the flu or flu-COVID combination vaccines in the U.S. due to regulatory delays. Bancel emphasized the importance of upcoming clinical milestones in oncology and rare diseases as well as the expected approvals of infectious disease vaccines in Europe and other regions.

Key Insights from Management’s Remarks

Management attributed Q4 performance to the strong launch of MNEXT Spike, expanded international partnerships, and disciplined cost reductions, while highlighting regulatory setbacks in the U.S. flu vaccine program.

• MNEXT Spike launch drives U.S. momentum: The mid-year approval and rapid uptake of MNEXT Spike established it as Moderna’s leading product in the U.S., with management reporting strong market share in the retail channel and significant penetration among adults aged 65 and older.
• International partnerships support growth: Strategic agreements in the U.K., Canada, and Australia enabled local manufacturing and supply, contributing to a more balanced geographic revenue mix and driving operational performance outside the U.S.
• Cost discipline yields margin improvement: Operating expenses declined 31% year over year, reflecting targeted productivity initiatives, inventory management, and prioritization of R&D investments, especially in infectious disease and oncology programs.
• Regulatory hurdles in flu vaccine: The FDA’s refusal to file letter for the mRNA-1010 flu vaccine in the U.S. created uncertainty around the product’s timeline and potential revenue contribution, though filings in Europe, Canada, and Australia remain under review.
• Pipeline advances in oncology and rare disease: The INT individualized cancer therapy program completed enrollment for three late-stage studies across melanoma, renal cell carcinoma, and bladder cancer, while collaborations in rare diseases (such as propionic acidemia) progressed toward pivotal data readouts.

Drivers of Future Performance

Moderna’s outlook is shaped by international expansion, new product launches, and a focus on pipeline execution amid ongoing regulatory and market risks.

• Geographic expansion fuels growth: Management expects revenue gains in 2026 to come primarily from international markets, with local manufacturing in the U.K. and Australia and a more balanced global revenue split. Strategic supply agreements, especially the U.K.’s spring and fall COVID vaccination campaigns, are set to drive volume growth.
• Pipeline progress and regulatory catalysts: Upcoming regulatory decisions on MNEXT Spike in Europe, Japan, and Taiwan, as well as filings for the combination flu-COVID vaccine and potential data readouts from late-stage oncology and rare disease programs, are expected to influence growth prospects. Management highlighted that approvals in these regions are critical given the lack of U.S. flu vaccine revenue assumed in guidance.
• Productivity and cost management: Ongoing adoption of AI tools and further cost reduction initiatives are expected to improve gross margins and support reinvestment in commercial and clinical development. However, management acknowledged that the timing and success of product launches and regulatory approvals remain key risks.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be watching (1) the pace and success of MNEXT Spike’s international expansion and regulatory approvals, (2) the outcome of ongoing regulatory reviews for flu and combination vaccines in Europe, Canada, and Australia, and (3) clinical milestone readouts from late-stage oncology and rare disease programs. Continued execution on cost discipline and AI-driven productivity improvements will also be important markers of progress.

Moderna currently trades at $42.34, up from $40.11 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.